Figure 1:



A
86.36
86.25
Relative Abundance
Time (min)
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
0
20
40
60
80
100
120
140
160
180
200
220

Figure 1 (continued):




Figure 1 (continued):





Figure 1 (continued):





Relative expression of ABCA13
0
5
10
15
artery
breast
esophagus
kidney
lymph node
ovary
pancreas
skin
uterine cervix
vein
NSCLC
Healthy tissues
NSCLC807
NSCLC812
NSCLC815
NSCLC827
NSCLC829
NSCLC830
NSCLC831
NSCLC832
NSCLC846
NSCLC860
NSCLC912
NSCLC914
NSCLC926
NSCLC975
NSCLC993
NSCLC1004
NSCLC1027
NSCLC1147
NSCLC1149
NSCLC1180
NSCLC1259

Figure 2a:



Relative expression of MMP12
0
100
200
300
400
500
adrenal gland
artery
bone marrow
brain, whole
breast
colon
esophagus
heart
kidney
leukocytes
liver
lung
lymph node
ovary
pancreas
placenta
prostate
salivary gland
skeletal muscle
skin
small intestine
spleen
stomach
testis
thymus
thyroid
urinary bladder
uterine cervix
uterus
vein
NSCLC8071
NSCLC8121
NSCLC8151
NSCLC8271
NSCLC8291
NSCLC8301
NSCLC8311
NSCLC8321
NSCLC8461
NSCLC8601
NSCLC9121
NSCLC9141
NSCLC9261
NSCLC9751
NSCLC9931
NSCLC10041
NSCLC10271
NSCLC11471
NSCLC11491
NSCLC11801
NSCLC12591
NSCLC
Healthy tissues

Figure 2b:



Percentage relative presentation ABCA13-001
0
50
100
adipose
brain
colon
kidney
PBMC
liver
nerve
pancreas
pleura
rectum
muscle
spleen
stomach
thymus
vein
normal lung
NSCLC

Figure 3a:



Percentage relative presentation MXRA5-001
150
100
50
0
adipose
brain
colon
kidney
PBMC
liver
nerve
pancreas
pleura
rectum
muscle
spleen
stomach
thymus
vein
normal lung
NSCLC

Figure 3b:



Percentage relative presentation DST-001
150
100
50
0
adipose
brain
colon
kidney
PBMC
liver
nerve
pancreas
pleura
rectum
muscle
spleen
stomach
thymus
vein
normal lung
NSCLC

Figure 3c:

Figure 4:



A*0201/CDK4-001
A*0201/Negative control stimulation
A*0201/CDK4-001 multimer 1
A*0201/CDK4-001 multimer 2
A*0201/ABCA13-001
A*0201/Negative control stimulation
A*0201/ABCA13-001 multimer 1
A*0201/ABCA13-001 multimer 2

Figure 5:



Binding Properties
relative binding score in %
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0.24
0.68
0.02
0.08
0.47
0.04
2.43
0.74
0.04
POSTN-002
MMP12-002
HLA-DR1
HLA-DR2
HLA-DR3
HLA-DR4
HLA-DR5
HLA-DR7

Figure 6:



Stability of HLA-Peptide Complex
stability ration in %
30.0
25.0
20.0
15.0
10.0
5.0
0.0
12.50
4.41
2.13
25.00
4.05
POSTN-002
MMP12-002
HLA-DR1
HLA-DR2
HLA-DR3
HLA-DR4
HLA-DR5
HLA-DR7

Figure 7:



CD154
TNF-alpha
CD4
4.36
79.2
0.083
16.7
3.1
80.9
0.063
16
0.19
82.8
0.041
17.4
0.011
83.5
0
16.6

Figure 7 (continued):





Figure 8:


Immunogenicity of Various Class II Peptides
Immune response rate in %
120.0
100.0
80.0
60.0
40.0
20.0
0.0
100
100
83
56
44
BIR-002
MET-005
CEA-006
TGFBI-004
MMP-001
IMA950 n = 16
IMA910 n = 71